Alliance Global Partners lowered the firm’s price target on Journey Medical (DERM) to $10 from $10.50 and keeps a Buy rating on the shares following the Q1 report. The firm adjusted its model lower due to Journey’s legacy business trends.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM: